2-hydroxy Flutamide

CAS No. 52806-53-8

2-hydroxy Flutamide( —— )

Catalog No. M20966 CAS No. 52806-53-8

2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 Get Quote
10MG 72 Get Quote
25MG 140 Get Quote
50MG 215 Get Quote
100MG 335 Get Quote
200MG 494 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    2-hydroxy Flutamide
  • Note
    Research use only, not for human use.
  • Brief Description
    2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.
  • Description
    2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    Androgen Receptor
  • Research Area
    Cancer
  • Indication
    Prostate Cancer

Chemical Information

  • CAS Number
    52806-53-8
  • Formula Weight
    292.21
  • Molecular Formula
    C11H11F3N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:25mg/ml(85.5 mM)
  • SMILES
    CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
  • Chemical Name
    2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Blobaum A L Byers F W Bridges T M et al. A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals 2015 43(11):1718.
molnova catalog
related products
  • Nandrolone phenpropi...

    Nandrolone phenpropionate is an androgen receptor agonist. It mainly used to treat women with breast cancer and osteoporosis.

  • LGD-4033

    A novel nonsteroidal, oral selective androgen receptor modulator (SARM), binds androgen receptor with high affinity (Ki=1 nM) and selectivity.

  • IMTPPE

    IMTPPE (SID 3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.